Out of 11 children with at least one post-treatment ... and adjusted revenue estimates for key products like Eylea and Dupixent. Meanwhile, Leerink Partners lowered its target to $762, keeping ...

Eylea’s sales in the United States declined ... The European Commission (EC) approved Dupixent to treat eosinophilic esophagitis in children aged 1 to 11 years, in November 2024.

We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Xolair is the only FDA-approved drug to reduce allergic reactions in children and adults with one ... ophthalmology drug Eylea. Positive data from additional studies bode well for the drug.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Currently enrolling children across sites in the U.S., United ... patent litigation and other related proceedings relating to EYLEA ® (aflibercept) Injection), the ultimate outcome of any such ...

Welcome to the Winter 2025 issue of “FCA Enforcement & Compliance Digest,” our quarterly newsletter in which we compile essential updates on ...

In children 12 years of age and older ... the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and ...